Furthermore, myricetin improved the paclitaxel chemotherapeutic ability of paclitaxel in human ovarian cancer cell lines by targeting multidrug resistance protein-1, in such a way that the expression of multidrug resistance protein-1 was considerably down-regulated compared to untreated cells and could be related to the increase in paclitaxel efficacy in ovarian cancer cells [115]. The gene discussed is ABCB1; the disease is ovarian cancer.